JPWO2021142257A5 - - Google Patents
Download PDFInfo
- Publication number
- JPWO2021142257A5 JPWO2021142257A5 JP2022542216A JP2022542216A JPWO2021142257A5 JP WO2021142257 A5 JPWO2021142257 A5 JP WO2021142257A5 JP 2022542216 A JP2022542216 A JP 2022542216A JP 2022542216 A JP2022542216 A JP 2022542216A JP WO2021142257 A5 JPWO2021142257 A5 JP WO2021142257A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- human subject
- composition according
- bone marrow
- marrow cells
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 229940124291 BTK inhibitor Drugs 0.000 claims description 20
- 210000002798 bone marrow cell Anatomy 0.000 claims description 20
- 102100031573 Hematopoietic progenitor cell antigen CD34 Human genes 0.000 claims description 16
- 101000777663 Homo sapiens Hematopoietic progenitor cell antigen CD34 Proteins 0.000 claims description 16
- 230000003211 malignant effect Effects 0.000 claims description 16
- 206010028537 myelofibrosis Diseases 0.000 claims description 14
- 229940121730 Janus kinase 2 inhibitor Drugs 0.000 claims description 10
- 201000007224 Myeloproliferative neoplasm Diseases 0.000 claims description 10
- 210000000952 spleen Anatomy 0.000 claims description 5
- 208000031261 Acute myeloid leukaemia Diseases 0.000 claims description 4
- 102100031650 C-X-C chemokine receptor type 4 Human genes 0.000 claims description 4
- 101000922348 Homo sapiens C-X-C chemokine receptor type 4 Proteins 0.000 claims description 4
- 108010008212 Integrin alpha4beta1 Proteins 0.000 claims description 4
- 238000009825 accumulation Methods 0.000 claims description 4
- 230000003247 decreasing effect Effects 0.000 claims description 4
- 230000005012 migration Effects 0.000 claims description 4
- 238000013508 migration Methods 0.000 claims description 4
- 230000035772 mutation Effects 0.000 claims description 4
- 210000005259 peripheral blood Anatomy 0.000 claims description 4
- 239000011886 peripheral blood Substances 0.000 claims description 4
- 208000003476 primary myelofibrosis Diseases 0.000 claims description 4
- 230000000694 effects Effects 0.000 claims description 3
- 150000003839 salts Chemical class 0.000 claims description 3
- 229940125814 BTK kinase inhibitor Drugs 0.000 claims description 2
- 208000032027 Essential Thrombocythemia Diseases 0.000 claims description 2
- 239000002144 L01XE18 - Ruxolitinib Substances 0.000 claims description 2
- 208000033776 Myeloid Acute Leukemia Diseases 0.000 claims description 2
- 208000017733 acquired polycythemia vera Diseases 0.000 claims description 2
- 208000037244 polycythemia vera Diseases 0.000 claims description 2
- HFNKQEVNSGCOJV-OAHLLOKOSA-N ruxolitinib Chemical compound C1([C@@H](CC#N)N2N=CC(=C2)C=2C=3C=CNC=3N=CN=2)CCCC1 HFNKQEVNSGCOJV-OAHLLOKOSA-N 0.000 claims description 2
- 229960000215 ruxolitinib Drugs 0.000 claims description 2
- 230000004936 stimulating effect Effects 0.000 claims description 2
- 238000002560 therapeutic procedure Methods 0.000 claims description 2
- 239000008194 pharmaceutical composition Substances 0.000 claims 29
- 230000003394 haemopoietic effect Effects 0.000 claims 7
- 210000001519 tissue Anatomy 0.000 claims 7
- 239000000203 mixture Substances 0.000 claims 2
- OXOXFDSEGFLWLU-UHFFFAOYSA-N 1-[4-[[[6-amino-5-(4-phenoxyphenyl)pyrimidin-4-yl]amino]methyl]-4-fluoropiperidin-1-yl]prop-2-en-1-one Chemical group C=1C=C(OC=2C=CC=CC=2)C=CC=1C=1C(N)=NC=NC=1NCC1(F)CCN(C(=O)C=C)CC1 OXOXFDSEGFLWLU-UHFFFAOYSA-N 0.000 claims 1
- 210000001185 bone marrow Anatomy 0.000 claims 1
- 239000003112 inhibitor Substances 0.000 claims 1
- 210000004185 liver Anatomy 0.000 claims 1
- 238000000034 method Methods 0.000 description 32
- 150000001875 compounds Chemical class 0.000 description 3
- 230000016396 cytokine production Effects 0.000 description 3
- 206010041660 Splenomegaly Diseases 0.000 description 2
- 102000004127 Cytokines Human genes 0.000 description 1
- 108090000695 Cytokines Proteins 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 230000014564 chemokine production Effects 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202062958632P | 2020-01-08 | 2020-01-08 | |
| US62/958,632 | 2020-01-08 | ||
| PCT/US2021/012696 WO2021142257A1 (en) | 2020-01-08 | 2021-01-08 | Methods of treating splenomegaly |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2023509968A JP2023509968A (ja) | 2023-03-10 |
| JPWO2021142257A5 true JPWO2021142257A5 (he) | 2024-01-17 |
Family
ID=76788747
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022542216A Pending JP2023509968A (ja) | 2020-01-08 | 2021-01-08 | 脾腫を治療する方法 |
Country Status (14)
| Country | Link |
|---|---|
| EP (2) | EP3980069A4 (he) |
| JP (1) | JP2023509968A (he) |
| KR (1) | KR20220130151A (he) |
| CN (1) | CN114423457A (he) |
| AU (1) | AU2021205484A1 (he) |
| BR (1) | BR112022013646A2 (he) |
| CA (1) | CA3164063A1 (he) |
| CO (1) | CO2022010592A2 (he) |
| CR (1) | CR20220374A (he) |
| IL (1) | IL294582A (he) |
| JO (1) | JOP20220168A1 (he) |
| MA (2) | MA57226B1 (he) |
| MX (1) | MX2022008490A (he) |
| WO (1) | WO2021142257A1 (he) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL294582A (he) * | 2020-01-08 | 2022-09-01 | Telios Pharma Inc | שיטות לטיפול בטחול מוגדל |
| US20240024314A1 (en) | 2020-01-08 | 2024-01-25 | Telios Pharma, Inc. | Methods of Treating Splenomegaly |
| WO2023071973A1 (en) * | 2021-10-26 | 2023-05-04 | Shenzhen Targetrx, Inc. | Fused bicyclic compound for inhibiting activity of tyrosine kinase |
| WO2024041614A1 (en) * | 2022-08-25 | 2024-02-29 | Beigene Switzerland Gmbh | Solid forms comprising (s) -7- (1-acryloylpiperidin-4-yl) -2- (4-phenoxyphenyl) -4, 5, 6, 7-tetrahydropyrazolo [1, 5-a] pyrimidine-3-carboxamide, and oxalic acid, compositions and methods of use thereof |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2015057992A1 (en) * | 2013-10-16 | 2015-04-23 | Izumi Raquel | Btk inhibitors for hematopoietic mobilization |
| HUE056329T2 (hu) * | 2014-08-11 | 2022-02-28 | Acerta Pharma Bv | BTK-inhibitor és BCL-2-inhibitor terápiás kombinációi |
| US9708348B2 (en) * | 2014-10-03 | 2017-07-18 | Infinity Pharmaceuticals, Inc. | Trisubstituted bicyclic heterocyclic compounds with kinase activities and uses thereof |
| WO2019243223A1 (en) * | 2018-06-19 | 2019-12-26 | Merck Patent Gmbh | Novel crystalline forms of 1-(4-{[6-amino-5-(4-phenoxy-phenyl)-pyrimidin-4-ylamino]-methyl}-4-fluoro-piperidin-1-yl)-propenone, salt forms thereof, and processes to obtain |
| TW202128156A (zh) * | 2019-11-14 | 2021-08-01 | 美商夸格智財控股有限公司 | 用於癌症治療之btk抑制劑及mdm2抑制劑之組合 |
| IL294582A (he) * | 2020-01-08 | 2022-09-01 | Telios Pharma Inc | שיטות לטיפול בטחול מוגדל |
-
2021
- 2021-01-08 IL IL294582A patent/IL294582A/he unknown
- 2021-01-08 WO PCT/US2021/012696 patent/WO2021142257A1/en active Application Filing
- 2021-01-08 JP JP2022542216A patent/JP2023509968A/ja active Pending
- 2021-01-08 CN CN202180004918.1A patent/CN114423457A/zh active Pending
- 2021-01-08 MX MX2022008490A patent/MX2022008490A/es unknown
- 2021-01-08 JO JOP/2022/0168A patent/JOP20220168A1/ar unknown
- 2021-01-08 EP EP21738476.7A patent/EP3980069A4/en active Pending
- 2021-01-08 CR CR20220374A patent/CR20220374A/es unknown
- 2021-01-08 EP EP22150344.4A patent/EP4000624A1/en active Pending
- 2021-01-08 AU AU2021205484A patent/AU2021205484A1/en active Pending
- 2021-01-08 MA MA57226A patent/MA57226B1/fr unknown
- 2021-01-08 MA MA63848A patent/MA63848A1/fr unknown
- 2021-01-08 KR KR1020227027305A patent/KR20220130151A/ko unknown
- 2021-01-08 BR BR112022013646A patent/BR112022013646A2/pt unknown
- 2021-01-08 CA CA3164063A patent/CA3164063A1/en active Pending
-
2022
- 2022-07-28 CO CONC2022/0010592A patent/CO2022010592A2/es unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2021155426A5 (he) | ||
| JP6141958B2 (ja) | 増殖性疾患の治療のための併用療法（ベムラフェニブ及びｍｄｍ２阻害剤） | |
| TWI241911B (en) | Sustained release ranolazine formulations | |
| IL294582A (he) | שיטות לטיפול בטחול מוגדל | |
| JP2019503365A5 (he) | ||
| JP5948246B2 (ja) | Ｂｃｒ−ａｂｌ、ｃ−ｋｉｔ、ｄｄｒ１、ｄｄｒ２またはｐｄｇｆ−ｒのキナーゼ活性によって仲介される増殖性障害およびその他の病態の治療方法 | |
| KR20150085833A (ko) | 룩솔리티니브의 서방성 제형 | |
| CN1350454A (zh) | 阿朴吗啡和西地拉非组合物 | |
| JP2009530331A (ja) | 自己免疫疾患を処置するための、少なくとも１種のｐｋｃ阻害剤および少なくとも１種のｊａｋ３キナーゼ阻害剤を含む医薬組合せ組成物 | |
| BR112013012854B1 (pt) | Composições farmacêuticas compreendendo inibidores de bcl-2 seletivos | |
| EA037152B1 (ru) | Способ лечения рака | |
| WO2007143146A2 (en) | Method of treating inflammatory diseases using tyroskine kinase inhibitors | |
| CA2677470A1 (en) | Methods of treatment using eszopiclone | |
| EA015715B1 (ru) | Твердая дисперсия, фармацевтическая композиция, включающая такую дисперсию, способ ее получения и применение для предотвращения и лечения заболеваний, связанных с бензодиазепиновыми рецепторами периферического типа | |
| TW200904430A (en) | Pharmaceutical compositions and method for treating, reducing, ameliorating, alleviating, or preventing dry eye | |
| JPWO2021142257A5 (he) | ||
| TWI302912B (en) | Therapeutic use | |
| US9375411B2 (en) | Uses and methods for the treatment of liver diseases or conditions | |
| JP6827113B2 (ja) | シェーグレン症候群の治療におけるペオニフロリン−６’−ｏ−ベンゼンスルホン酸の使用 | |
| WO2013074432A1 (en) | Immediate release 4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]-n-[5-(4-methyl- 1h-imidazol-1-yl)-3-(trifluoromethyl)phenyl] benzamide formulation | |
| CN109876000A (zh) | 帕布昔利布在黏膜恶性黑色素瘤中的应用 | |
| WO2020238932A1 (zh) | Parp抑制剂联合vegfr抑制剂用于治疗卵巢癌或乳腺癌的用途 | |
| KR20230145439A (ko) | Irak4 분해제 및 이의 용도 | |
| JPWO2019213074A5 (he) | ||
| CA2672716A1 (fr) | Nouvelle utilisation therapeutique pour le traitement des leucemies |